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prescription (OCS) or hospitalisation, no change in maintenance
therapy and a mean daily short-acting b2-agonist (SABA) con-
sumption < 0.5 doses/day. Baseline demographics, co-morbidity
and asthma medication before TI was used to construct regres-
sion models to control for factors potentially inﬂuencing out-
comes. RESULTS: Respectively, 2701 and 7320 patients were
included in the BUD/FORM and SAL/FLU cohorts, respectively,
with no signiﬁcant difference in age, gender, co-morbidity, ICS
dose, SABA use or hospitalisations at baseline while active
smokers, asthma consultations and OCS prescriptions were
slightly lower in the BUD/FORM group. Use of SABA and
asthma consultations decreased in both cohorts following TI. In
unadjusted analysis a higher proportion of treatment success was
seen in the BUD/FORM group following TI compared to SAL/
FLU (25.3 vs. 23.0%, p < 0.05). This result was driven by fewer
patients in the BUD/FORM group with an OCS prescription and
high SABA use. In multivariate binary regression analysis, BUD/
FORM was not signiﬁcantly associated with greater odds of
success than SAL/FLU (OR, 95% CI: 1.11, 0.99–1.23). Variables
signiﬁcantly associated with success were age, female sex, no
rhinitis and low OCS and SABA use pre TI. Resource use (hos-
pitalisations and asthma consultations) was similar between
groups post TI. CONCLUSION: Initiating treatment with BUD/
FORM or SAL/FLU in real-life practice improved outcomes to a
similar magnitude, although there were trends to better outcomes
associated with BUD/FORM.
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OBJECTIVES: Patients with pneumonia and respiratory failure
usually require intensive care unit (ICU) admission. Because of
high acuity and the need for expensive interventions, concern
exists over the ability of DRG reimbursement to cover inpatient
costs. This study evaluated the costs and DRG reimbursement
associated with the care of pneumonia and concurrent respira-
tory failure. METHODS: Forty-six consecutive patients with
complete data sets enrolled in the VALID study, a phase III
multicenter study evaluating recombinant SP-C-based surfactant
treatment (Venticute®, ALTANA, Konstanz, Germany) in
patients with pneumonia and respiratory failure, in 9/2006 were
included. Total costs (ICU/non-ICU) were assessed, assumed
daily costs were $1,238 (US$) for ICU without ventilation,
$2,760 with ventilation, $1,004 for stepdown, and $770 for
ward. FY07 reimbursement was determined by multiplying the
relative weight for each DRG code by a base rate of US$6,000.
For outlier payment calculations, the threshold for FY2006 of
$23,300.00 was used. Costs above regular reimbursement plus
this threshold were reimbursed at 80%. RESULTS: Mean age
was 53.2 + 16.3 (mean + SD), with a mean APACHE II score of
17.4 + 6.4. Mean hospital LOS = 29 days, with mean ICU, step-
down, and ward LOS of 22, 2 and 5 days respectively. Mean
duration of ventilation was 17 days (range 2–49). Total costs
averaged $58,242, with 46.1% of all costs accounting for ICU
care (excluding ventilation), 44.0% for ventilation, and 103.5%
and 6.4% for stepdown and ward respectively. Across all DRGs,
the average shortfall (cost minus reimbursement) equaled
$20,897 with a loss occurring in 36/47 (76.6%) patients. CON-
CLUSION: This preliminary analysis suggests that DRGs fail to
cover costs associated with pneumonia and respiratory failure.
This potentially places hospitals that care for these patients at
signiﬁcant ﬁnancial risk and suggests the needs for revision in
reimbursement schemes to insure a more equitable payment rela-
tive to expected resource consumption.
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OBJECTIVES: It is hypothesised that socio-economic factors
play a key role in determining treatment patterns. This study
investigated the impact of employment and gender on asthma
treatment patterns in 2526 patients in the US, Germany and
Spain. METHODS: The data were drawn from the Adelphi
Disease Speciﬁc Programme (DSP) in asthma, a cross-sectional
study of consulting patients undertaken in 2007. Data were
collected by doctors who were asked to include the next 6
patients consulting for asthma from a speciﬁed start date. Key
factors analysed were gender and employment status (skilled,
unskilled, and unemployed). Chi-square and Fisher’s exact tests
were used to test for differences. RESULTS: There was a signiﬁ-
cant relationship between employment status and patients’ level
of knowledge about their condition. Skilled workers had a higher
level of knowledge as compared to unskilled workers (US: 37.3%
vs. 18.3%, p < 0.001; Germany: 35.3% vs. 22.5%, p < 0.05;
Spain: 26.7% vs. 15.9%, p = 0.06). Skilled workers also had
more involvement in treatment decisions (US: 50.0% vs. 32.3%,
p < 0.001; Germany: 35.3% vs. 18.8%, p < 0.001; Spain: 21.6%
vs. 13.4%, p = 0.1) and were rated more compliant than
unskilled workers (US: 56.3% vs. 37.1%, p < 0.001; Germany:
45.3% vs. 28.4%, p < 0.01; Spain: 35.1% vs. 23.2%, p = 0.06).
There were no signiﬁcant differences between genders other than
Spain where signiﬁcantly more men had a higher level of knowl-
edge about their condition (24.5% vs. 17.2%, p < 0.01) and
more involvement in their treatment (20.9% vs. 14.5%,
p < 0.05). In all countries a signiﬁcant positive correlation was
found between level of involvement and compliance with treat-
ment (p < 0.01). CONCLUSION: There are signiﬁcant differ-
ences in knowledge, involvement and compliance between socio-
economic groups in the US, Germany and Spain. The signiﬁcant
correlation between level of involvement and compliance may
indicate that if physicians made particular efforts with lower
socio-economic groups in treatment decisions compliance levels
would improve.
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OBJECTIVES: To compare medical costs and utilization in
patients on single controller inhaled corticosteroid (ICS) to other
asthma drug regimens. Medical costs and health care utilization
associated with asthma and the variation by treatment are poorly
understood. METHODS: Direct medical costs and utilization
were captured from administrative electronic databases from
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continuously-enrolled health plan members with asthma aged 5
years or older with comprehensive medical and drug coverage.
Asthma patients were identiﬁed during 2002, categorized into 14
asthma drug treatment groups based on 2003 prescription
records, and had total medical costs and utilization determined in
2004, adjusting for demographics, insurance types, asthma risk,
co-morbidity, and treatment selection propensity scores.
RESULTS: In total, 96,631 patients met the study eligibility
criteria. Patients averaged 37.5 + 23.1 years of age and were
57% female, 14% Medicare, 4% Medicaid, and had a median
family income of $64,967 + 29,285. Total unadjusted direct
medical costs/patient/year averaged $3745 ($3298 low asthma
risk versus $6797 high asthma risk, p < 0.0001). Adjusted total
and asthma-related costs were signiﬁcantly lower with single
controller ICS compared to single controller leukotriene modiﬁ-
ers (p < 0.0001) and most combination controller regimens
(p < 0.05 to p < 0.0001). Additionally, single controller ICS com-
pared to single controller leukotriene modiﬁers and combination
controllers was associated with signiﬁcantly lower asthma-
related utilization. CONCLUSION: Both costs and asthma-
related utilizations are signiﬁcantly less in the year after being
dispensed single controller ICS compared to single controller
leukotriene modiﬁers or combination controllers. These ﬁndings
from a typical practice setting provide economic support for
international guidelines that recommend single controller ICS as
the preferred initial asthma controller treatment.
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